EMILY BROACH: Open Payments
NPI 1356128862 · HAVERTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,044 in 137 payments from 19 companies in 2025. Trend: 2023 $685 · 2024 $2,987 · 2025 $3,044
Food & beverage: $2,955Education: $89
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 29 | $772 |
| GENZYME CORPORATION | 10 | $416 |
| GlaxoSmithKline, LLC. | 22 | $415 |
| Regeneron Healthcare Solutions, Inc. | 15 | $300 |
| Novartis Pharmaceuticals Corporation | 12 | $208 |
| CSL Behring | 7 | $174 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $156 |
| Optinose US, Inc. | 13 | $151 |
| Genentech USA, Inc. | 3 | $66 |
| BioCryst US Sales Co., LLC | 2 | $56 |
Products named: DUPIXENT, FASENRA, TRELEGY ELLIPTA, Xhance, NEFFY, TEZSPIRE, NUCALA, XOLAIR.
Industry payments across PA — which companies pay providers there.
